JAN 1 6 2002 E IN THE UNITED STATES

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Seishi Kato et al.

Application Serial No: 09/254,760

Filing Date: April 16, 1999

For: Human Proteins Having Secretory Signal Sequences And DNAs Encoding These Proteins

Attorney Docket No.: GIN-6704CPUS

Commissioner for Patents Office of Petitions Box DAC Washington, D.C. 20231 Group Art Unit: 1642

Examiner: Wesley Lazar, Ph.D.

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Office of Petitions, Box DAC, Washington, D.C. 20231 on the date set forth below.

November 2, 2001

Date of Signature and of Mail Deposit

By:

Cynthia L. Kanik, Ph.D.

Reg. No. 37,320

Attorney for Applicant

PETITION TO REVIVE AN ABANDONED APPLICATION PURSUANT TO 37 CFR § 1.137(b)

HECEIVED

Dear Sir:

On April 16, 1999, Application Serial No. 09/254,760, claiming priority to PCEPUTY A/C PATENTS

Application No. PCT/JP97/03239 (filed 12 September 1997), was filed on behalf of Sagami

Chemical Research Center. A Notice of Abandonment (Paper No. 7) was issued on May 22.

27 CFR §1.137(b).

· U.S. Serial No.: 09/155,00

Under 37 CFR §1.137(b), a Petition to Revive an unintentionally abandoned application must be accompanied by: (1) any required reply, unless it has been previously submitted; (2) a petition fee as set forth in 37 CFR §1.17(m); (3) a statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to this paragraph was unintentional; and (4) any terminal disclaimer under paragraph (c) of this section.

Accordingly, Applicants submit with this Petition to Revive the following:

- (1) an Amendment and Response to the Office Communication dated June 2, 2000 (Paper No. 5);
- (2) a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
 - (3) a transmittal letter for diskette containing the substitute Sequence Listing;
 - (4) a paper copy of a substitute Sequence Listing (pages 1 to 28);
- (5) a diskette containing a computer readable form (CRF) of the substitute Sequence Listing;
 - (6) a check for the amount of \$904.00 for the additional independent claims; and
 - (7) a check for the amount of \$1,280.00 for the petition fee under 37 C.F.R. \$1.17(m).

It is respectfully submitted that the entire delay in filing the response until the filing of this petition was unintentional and the present petition is being filed within one year of the date of abandonment. A terminal disclaimer is not required under 37 CFR §1.137(c) because the subject application was filed after June 8, 1995.

herewith. Enclosed is a check which covers the appropriate fee of \$1,280,00 based on large

entity status. Please charge any underpayments or credit any overpayments to our Deposit Account No. 12-0080. A duplicate of this sheet is enclosed.

If Applicants' undersigned attorney can be of assistance in furthering the prosecution of this application, the Examiner is invited to contact her at the telephone number listed below.

Pagastfully submitted

LAHIVE & COCKFIELD, LLP

Cynthia L. Kanik, Ph.D.

Registration No. 37,320 Attorney for Applicants

28 State Street Boston, MA 02109 Tel. (617) 227-7400

Dated: November 2, 2001